STAT

3 trends to watch in pharma advertising in 2018

Can drug companies make you forget you're actually watching an ad? They're going to try. Check out our list of pharma marketing tactics to watch in 2018.

As the year winds down, STAT reporters are taking a look at the stories they’re most eager to track in 2018. Find all our “three to watch” series here

These are boom times for the multibillion-dollar drug advertising industry — and the parade of ads across your TV screen shows no sign of slowing down in 2018.

But while the money keeps flowing, there are changes

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About A GLP-1 Side Effect, U.K. Clinical Trial Transparency, And More
A new study links GLP-1 drugs like Ozempic to a higher risk of aspiration pneumonia — a lung infection caused by food breathed into the lungs — after endoscopies.
STAT1 min read
STAT+: Medicare Expected To Negotiate Obesity Drug Prices Soon, New Analysis Predicts
Medicare will likely choose the obesity drug semaglutide for price negotiation “within the next few years,” according to a new analysis.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About An AstraZeneca Deal, A WHO Pandemic Pact, And More
AstraZeneca agreed to acquire Fusion Pharmaceuticals in a deal worth more than $2 billion, picking up a company focused on targeted radiation therapies for cancer.

Related